SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Orthofix Medical Inc. – ‘8-K’ for 1/3/23 – ‘EX-10.3’

On:  Thursday, 1/5/23, at 6:08am ET   ·   For:  1/3/23   ·   Accession #:  1193125-23-1900   ·   File #:  0-19961

Previous ‘8-K’:  ‘8-K’ on / for 1/4/23   ·   Next:  ‘8-K’ on / for 1/9/23   ·   Latest:  ‘8-K’ on / for 5/7/24   ·   9 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/05/23  Orthofix Medical Inc.             8-K:1,2,5,8 1/03/23   15:393K                                   Donnelley … Solutions/FA

Current Report   —   Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     66K 
 2: EX-10.1     Material Contract                                   HTML     82K 
 3: EX-10.2     Material Contract                                   HTML     17K 
 4: EX-10.3     Material Contract                                   HTML     16K 
 5: EX-10.4     Material Contract                                   HTML     16K 
 6: EX-99.1     Miscellaneous Exhibit                               HTML     24K 
10: R1          Document and Entity Information                     HTML     46K 
13: XML         IDEA XML File -- Filing Summary                      XML     13K 
11: XML         XBRL Instance -- d433449d8k_htm                      XML     14K 
12: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 8: EX-101.LAB  XBRL Labels -- ofix-20230103_lab                     XML     54K 
 9: EX-101.PRE  XBRL Presentations -- ofix-20230103_pre              XML     34K 
 7: EX-101.SCH  XBRL Schema -- ofix-20230103                         XSD     13K 
14: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    19K 
15: ZIP         XBRL Zipped Folder -- 0001193125-23-001900-xbrl      Zip     67K 


‘EX-10.3’   —   Material Contract


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  EX-10.3  

Exhibit 10.3

 

LOGO

December 30, 2022

John Bostjancic

c/o SeaSpine Holdings Corporation

5770 Armada Drive

CarlsbadCA 92008

Dear John,

Per our discussions, it gives me great pleasure to present this offer to join Orthofix Medical Inc. (“Parent” and, together with its direct and indirect current and future subsidiaries, and giving effect to any change of name that may occur in the future, the “Company”). This offer is made in connection with the pending merger of your current employer, SeaSpine Holdings Corporation or a direct or indirect subsidiary thereof (“SeaSpine”), into a wholly owned subsidiary of the Company (the “Merger”), and is made contingent upon and subject to the closing of the Merger (the “Closing”) pursuant to the terms of the merger agreement between the Company, SeaSpine and the aforementioned Company subsidiary (the “Merger Agreement”).

Starting Date: Your starting date as Parent’s Chief Financial Officer (the “Position”) will be on the date that the Closing occurs (the “Closing Date”). We currently anticipate that the Closing will occur in January 2023, subject to, among other things, the stockholders of SeaSpine adopting the Merger Agreement and the stockholders of the Company approving the issuance of shares of common stock of Parent (“Parent Common Stock”) that will occur in the Merger, in each case, at the respective special meeting of stockholders currently scheduled for January 4, 2023.

Compensation: Your compensation will be determined by the Compensation & Talent Development Committee (the “Compensation Committee”) of the Company’s Board of Directors (the “Board”). The Compensation Committee has approved the following compensation arrangements for you, effective as of the Closing:

Base Salary: An initial annual base salary of $500,000 to be paid in accordance with the Company’s regular payroll practices and less applicable deductions and tax withholdings.

Cash Incentive Bonus: You will be eligible to receive annual bonus compensation under and subject to the terms and conditions of the Company’s annual cash incentive program based on the achievement of goals established by the Compensation Committee and/or the Board from time-to-time. For 2023, your target bonus opportunity under the program will be equal to 70% of your annual base salary amount.

 

LOGO


LOGO

 

Equity Awards: You will be eligible to receive stock-based compensation, whether restricted stock units, performance-based stock units, stock options or otherwise, under the Company’s 2012 Long Term Incentive Plan, as amended, or other stock-based compensation plans that the Company may establish from time-to-time. In addition, to induce your acceptance of employment with the Company effective upon the Closing, the Compensation Committee has approved grants to you, effective upon and as of the close of business on the Closing Date, of (i) restricted stock units that settle in shares of Parent Common Stock (the “Sign-On RSUs”) and (ii) stock options to purchase shares of Parent Common Stock (the Sign-On Common Stock,” and collectively with the Sign-On RSUs, the “Sign-On Award”). The Sign-On RSUs will vest in annual 33 1/3% installments over three years, and 1/3 of the Sign-On Stock Options will vest on the first anniversary the Closing Date, and remaining 2/3 of the Sign-On Stock Options will vest in eight equal quarterly installments thereafter, subject to your continued employment on each applicable vesting date. Notwithstanding anything in any agreement with or plan of SeaSpine to the contrary (including the SLRSP, as defined below), the Sign-On Award will not be subject to any automatic accelerated vesting without continued service through an applicable vesting date except in cases of (i) involuntary termination following a future “Change in Control” (as defined in the Company’s most recently publicly filed form of Change in Control and Severance Agreement (the “CIC and Severance Agreement”)) that occurs with respect to the Company after the Closing Date, (ii) death, or (iii) disability. The grant date value of the Sign-On RSUs will be $750,000 and the grant date value of the Sign-On Stock Options will be $750,000 (in each case, subject to rounding to the nearest whole share), for a total grant value of $1,500,000. The Sign-On Award and future stock-based compensation grants made to you, will be subject to the terms and conditions of applicable plan documents and award agreements, which will be separately made available to you.

Change in Control and Severance Agreement: As of the Closing Date, you will remain a “Participant” under SeaSpine’s Senior Leadership Retention and Severance Plan (the “SLRSP”). In consideration for the offer being made by the Company pursuant to this letter and your acceptance of such offer, the Company and you agree that (i) (A) your acceptance and performance of the Position, and (B) any future reduction of your equity-based compensation solely as a result of across-the-board reductions to equity-based compensation levels that apply the applicable reduction percentage substantially similarly to all executives, shall in the case of each of clauses (A) and (B) not provide you with “Good Reason” under the SLRSP, (ii) the Merger shall constitute a “Change in Control” under the SLRSP, and following the Merger you will maintain the rights related thereto as set forth in the SLRSP, except that the provisions of and rights contained in Section 4 of the SLRSP (taking into account the provisions of Section 7 of the SLRSP) shall not apply with respect to the Sign-On Award or any other Company equity-based compensation granted to you by the Company after the Closing Date unless a future “Change in Control” (as defined in the CIC and Severance Agreement) occurs with respect to the Company after the Closing Date. Notwithstanding the foregoing, it is the intent of the Company to offer you the ability to enter into, within sixty (60) days of the Closing Date, a new agreement that is substantially equivalent to the CIC and Severance Agreement, which if entered into, would supersede

 

LOGO


LOGO

 

your rights under the SLRSP (though the new CIC and Severance Agreement will memorialize that you will remain protected under the new agreement during the two-year period following the Merger in the same manner that you are during the one-year “Protection Period” under the SLRSP, i.e., you will be in a “CIC Period” under the new CIC and Severance Agreement for two years). The final terms of such CIC and Severance Agreement will be subject to review and approval by the Compensation Committee, as constituted following the Closing. Notwithstanding the foregoing, you understand and acknowledge that, if you become employed by the Company, you will be an “at-will” employee at all times during your employment.

D&O Indemnification Agreement: Under separate cover, you will receive a D&O Indemnification Agreement.

We very much look forward to working with you following consummation of the Merger.

Sincerely,

/s/ Michael E. Paolucci

Michael E. Paolucci

Chair of the Compensation Committee

 

ACKNOWLEDGED, ACCEPTED, AND AGREED:
/s/ John Bostjancic
John Bostjancic

 

LOGO


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:1/5/23
1/4/238-K,  S-8
For Period end:1/3/23
12/30/22
 List all Filings 


7 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/05/24  Orthofix Medical Inc.             10-K       12/31/23  120:20M                                    Donnelley … Solutions/FA
 1/12/24  Orthofix Medical Inc.             S-8         1/12/24    8:693K                                   Donnelley … Solutions/FA
 1/08/24  Orthofix Medical Inc.             S-8         1/08/24    8:692K                                   Donnelley … Solutions/FA
11/08/23  Orthofix Medical Inc.             S-8        11/08/23    4:237K                                   Donnelley … Solutions/FA
 3/06/23  Orthofix Medical Inc.             10-K       12/31/22  134:28M                                    Donnelley … Solutions/FA
 1/10/23  Orthofix Medical Inc.             S-8         1/10/23    8:354K                                   Donnelley … Solutions/FA
 1/10/23  Orthofix Medical Inc.             S-8 POS     1/10/23    9:591K                                   Donnelley … Solutions/FA


2 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/04/23  Orthofix Medical Inc.             S-8         1/04/23    7:645K                                   Donnelley … Solutions/FA
10/11/22  Orthofix Medical Inc.             8-K:1,5,8,910/10/22   13:1.1M                                   Donnelley … Solutions/FA
Top
Filing Submission 0001193125-23-001900   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., May 12, 2:49:04.2am ET